it is now being proposed that [TAVR] is likely to be the preferred option [to open heart surgery].
Yes, that is what we're saying.
Costs aren't just from comparing the operation and inclusions per se. It's the LT trajectory, risk to the patient etc. That reflects in hospitalisation and morbidity figures and overall costs. Thank you.
News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval, page-472
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
